Skip to main content

Table 2 Frequency of mentions and prevalence of signs/symptoms and life impacts in the selected publications

From: Development of a preliminary conceptual model of the patient experience of chronic kidney disease: a targeted literature review and analysis

  Overall Subpopulationsa
(N = 100) General (N = 48) Diabetes (N = 11) Anaemia (N = 7) CKD 1–3 (N = 9) CKD 4–5 (N = 14) Dialysis (N = 26)
  Freq. Prev. Freq. Prev. Freq. Prev. Freq. Prev. Freq. Prev. Freq. Prev. Freq. Prev.
Signs/symptomsb
 Pain/discomfort 57 73 58 75 36 NR 71 68 44 60 57 100 73 75
 Tiredness/low energy/lethargy/fatigue 42 100 31 100 27 NR 86 50 22 24 36 76 62 71
 Disturbed sleep/sleep-related problems 28 94 33 94 11 55 29 66 38 80
 Itching/skin problems 25 89 17 89 18 NR 22 NR 29 84 42 83
 Muscular pain/cramps 18 89 17 89 18 44 11 55 7 83 31 69
 Appetite loss/anorexia 18 67 15 67 9 NR 21 32 35 53
 Nausea 18 59 8 38 18 NR 21 59 38 42
 Dyspnoea/shortness of breath 17 80 12 67 9 36 14 NR 21 80 31 66
 Feeling unwell 7 55 4 NR 27 52 11 NR 7 NR 8 36
 Dizziness 7 50 27 50
Life impactsb
 Anxiety/depression 49 83 56 39 27 83 14 NR 55 33 43 65 54 57
 Mental impact 26 26 27 21 55 26 43 NR 7 NR 23 NR
 Mood change/irritability 12 50 10 50 36 NR 11 NR 14 NR 8 24
 Physical functioning 43 83 52 83 55 NR 86 NR 22 61 14 NR 35 14
 Emotional interference 37 82 35 82 45 NR 43 NR 14 NR 54 45
 Social relationship interference 34 60 31 89 64 NR 57 83 11 26 7 NR 38 28
 Cognitive impairment (memory, concentration, confusion) 27 61 31 71 9 36 33 14 14 NR 35 52
 General health perception 26 36 27 19 27 NR 57 NR 11 NR 7 NR 31 36
ADL/daily/regular activities 24 80 25 46 28 83 33 49 14 80 38 60
 Diet/food changes/related 23 83 23 74 36 43 7 40 27 48
 Vitality 23 60 19 24 36 NR 86 60 22 NR 14 NR 23 NR
 Mobility problems 16 100 21 61 9 NR 14 NR 33 45 21 100 19 70
 Self-care issues 10 88 8 NR 9 NR 28 NR 22 18 21 68 12 88
 Activity impairment 9 89 6 89 18 NR 43 22 11 52 7 48 12 52
  1. Freq. (frequency): values indicate the proportion (%) of publications in which each sign/symptom or life impact was mentioned (−, not mentioned)
  2. Prev. (prevalence): values indicate the highest observed prevalence (%) of the signs/symptoms or life impacts in the publications (−, not mentioned). Prevalence values of 50% or above are highlighted in bold
  3. aPublications could report data for more than one subpopulation
  4. bSigns/symptoms and life impacts mentioned in at least 25% of the publications for any subpopulation were included
  5. ADL activities of daily living, CKD chronic kidney disease, freq. frequency, prev. prevalence, NR not reported